Logo image of FDMT

4D MOLECULAR THERAPEUTICS IN (FDMT) Stock Fundamental Analysis

NASDAQ:FDMT - Nasdaq - US35104E1001 - Common Stock - Currency: USD

4.38  +0.1 (+2.34%)

After market: 4.19 -0.19 (-4.34%)

Fundamental Rating

3

FDMT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 558 industry peers in the Biotechnology industry. While FDMT has a great health rating, there are worries on its profitability. FDMT has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

FDMT had negative earnings in the past year.
FDMT had a negative operating cash flow in the past year.
In the past 5 years FDMT always reported negative net income.
In the past 5 years FDMT always reported negative operating cash flow.
FDMT Yearly Net Income VS EBIT VS OCF VS FCFFDMT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

1.2 Ratios

With a decent Return On Assets value of -34.21%, FDMT is doing good in the industry, outperforming 62.19% of the companies in the same industry.
FDMT has a better Return On Equity (-37.56%) than 72.40% of its industry peers.
Industry RankSector Rank
ROA -34.21%
ROE -37.56%
ROIC N/A
ROA(3y)-33.14%
ROA(5y)-27.85%
ROE(3y)-36.91%
ROE(5y)-31.04%
ROIC(3y)N/A
ROIC(5y)N/A
FDMT Yearly ROA, ROE, ROICFDMT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400 600 800 1K

1.3 Margins

FDMT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FDMT Yearly Profit, Operating, Gross MarginsFDMT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -100K -200K -300K -400K -500K

More info and screens

7

2. Health

2.1 Basic Checks

FDMT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, FDMT has more shares outstanding
FDMT has more shares outstanding than it did 5 years ago.
FDMT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
FDMT Yearly Shares OutstandingFDMT Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
FDMT Yearly Total Debt VS Total AssetsFDMT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

FDMT has an Altman-Z score of 0.36. This is a bad value and indicates that FDMT is not financially healthy and even has some risk of bankruptcy.
FDMT's Altman-Z score of 0.36 is fine compared to the rest of the industry. FDMT outperforms 63.44% of its industry peers.
There is no outstanding debt for FDMT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.36
ROIC/WACCN/A
WACC9.68%
FDMT Yearly LT Debt VS Equity VS FCFFDMT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

FDMT has a Current Ratio of 12.36. This indicates that FDMT is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of FDMT (12.36) is better than 84.23% of its industry peers.
FDMT has a Quick Ratio of 12.36. This indicates that FDMT is financially healthy and has no problem in meeting its short term obligations.
FDMT has a better Quick ratio (12.36) than 84.23% of its industry peers.
Industry RankSector Rank
Current Ratio 12.36
Quick Ratio 12.36
FDMT Yearly Current Assets VS Current LiabilitesFDMT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

3

3. Growth

3.1 Past

FDMT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -31.40%.
Looking at the last year, FDMT shows a very negative growth in Revenue. The Revenue has decreased by -99.94% in the last year.
FDMT shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -64.95% yearly.
EPS 1Y (TTM)-31.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-30.3%
Revenue 1Y (TTM)-99.94%
Revenue growth 3Y-87.29%
Revenue growth 5Y-64.95%
Sales Q2Q%-50%

3.2 Future

The Earnings Per Share is expected to decrease by -5.47% on average over the next years.
The Revenue is expected to grow by 133.60% on average over the next years. This is a very strong growth
EPS Next Y-21.75%
EPS Next 2Y-14.65%
EPS Next 3Y-10.47%
EPS Next 5Y-5.47%
Revenue Next Year176.83%
Revenue Next 2Y43.18%
Revenue Next 3Y36.87%
Revenue Next 5Y133.6%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
FDMT Yearly Revenue VS EstimatesFDMT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
FDMT Yearly EPS VS EstimatesFDMT Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for FDMT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FDMT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FDMT Price Earnings VS Forward Price EarningsFDMT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FDMT Per share dataFDMT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

FDMT's earnings are expected to decrease with -10.47% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-14.65%
EPS Next 3Y-10.47%

More info and screens

0

5. Dividend

5.1 Amount

FDMT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

4D MOLECULAR THERAPEUTICS IN

NASDAQ:FDMT (7/14/2025, 8:00:02 PM)

After market: 4.19 -0.19 (-4.34%)

4.38

+0.1 (+2.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-07 2025-08-07/amc
Inst Owners95.97%
Inst Owner Change0.05%
Ins Owners3.88%
Ins Owner Change0%
Market Cap202.88M
Analysts80
Price Target30.15 (588.36%)
Short Float %8.73%
Short Ratio8.49
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.83%
Min EPS beat(2)-7.88%
Max EPS beat(2)2.21%
EPS beat(4)2
Avg EPS beat(4)-0.98%
Min EPS beat(4)-10.47%
Max EPS beat(4)12.21%
EPS beat(8)6
Avg EPS beat(8)9.61%
EPS beat(12)8
Avg EPS beat(12)7.53%
EPS beat(16)12
Avg EPS beat(16)9.63%
Revenue beat(2)0
Avg Revenue beat(2)-98.18%
Min Revenue beat(2)-99.94%
Max Revenue beat(2)-96.41%
Revenue beat(4)0
Avg Revenue beat(4)-98.86%
Min Revenue beat(4)-99.94%
Max Revenue beat(4)-96.41%
Revenue beat(8)2
Avg Revenue beat(8)58.41%
Revenue beat(12)2
Avg Revenue beat(12)17.56%
Revenue beat(16)5
Avg Revenue beat(16)198.01%
PT rev (1m)-3.62%
PT rev (3m)-9.62%
EPS NQ rev (1m)-0.13%
EPS NQ rev (3m)1.23%
EPS NY rev (1m)-0.2%
EPS NY rev (3m)0.34%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.36%
Revenue NY rev (1m)-22.23%
Revenue NY rev (3m)-12.59%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8820.94
P/FCF N/A
P/OCF N/A
P/B 0.43
P/tB 0.43
EV/EBITDA N/A
EPS(TTM)-3.18
EYN/A
EPS(NY)-3.92
Fwd EYN/A
FCF(TTM)-3.39
FCFYN/A
OCF(TTM)-3.31
OCFYN/A
SpS0
BVpS10.14
TBVpS10.14
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -34.21%
ROE -37.56%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.14%
ROA(5y)-27.85%
ROE(3y)-36.91%
ROE(5y)-31.04%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 50.88%
Cap/Sales 16117.4%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.36
Quick Ratio 12.36
Altman-Z 0.36
F-Score2
WACC9.68%
ROIC/WACCN/A
Cap/Depr(3y)195.17%
Cap/Depr(5y)250.86%
Cap/Sales(3y)3538.16%
Cap/Sales(5y)2134.47%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-31.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-30.3%
EPS Next Y-21.75%
EPS Next 2Y-14.65%
EPS Next 3Y-10.47%
EPS Next 5Y-5.47%
Revenue 1Y (TTM)-99.94%
Revenue growth 3Y-87.29%
Revenue growth 5Y-64.95%
Sales Q2Q%-50%
Revenue Next Year176.83%
Revenue Next 2Y43.18%
Revenue Next 3Y36.87%
Revenue Next 5Y133.6%
EBIT growth 1Y-3.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-23.14%
EBIT Next 3Y-16.47%
EBIT Next 5YN/A
FCF growth 1Y-61.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-68.32%
OCF growth 3YN/A
OCF growth 5YN/A